RT @RichardPAConway: Preito-Pena at al. Tocilizumab in LVV-GCA and TAK. Similar responses in both, with 75% showing comp
Tweet Content
Preito-Pena at al. Tocilizumab in LVV-GCA and TAK. Similar responses in both, with 75% showing complete clinical response but only 20% complete imaging response at month 12. Clinical implications of these persistent imaging findings need clarification @RheumNow #EULAR2022 POS0804 https://t.co/sNbRzIkwnt
Show on Archive Page
On
Display in Search Results
On
PDQ
Off